The first patient in a prospective, randomized, controlled trial of Medtronic's Arctic Front Advance cryoballoon has been enrolled at The Ohio State University Wexner Medical Center. The 210-patient, 30-site US trial seeks to assess use of the device as a first-line treatment for symptomatic paroxysmal atrial fibrillation, compared with antiarrhythmic drug therapy, for 12 months.
Study begins for Medtronic's Arctic Front Advance cryoballoon
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.